

Curriculum Vitae

Name: Neil Harrison Bander

Place of Birth: Boston, Massachusetts

Nationality: USA

Office Address: Weill Medical College of Cornell University
P.O. Box 23
525 East 68th Street,
New York, New York 10065

Licensed Physician: Year: 1974 Place of Issue: New York

Board Certification: Year: 1983 Name: American Board of Urology

Education:

Johns Hopkins University
1969, B.A. (Biology)

University of Connecticut Medical School
1974, M.D.

Postdoctoral Training:

1974-77 Intern (1974-75); Junior Resident (1975-76); Resident (1976-77),
General Surgery
New York University-Bellevue Medical Center

1977-80 Resident, Urology (1977-78); Senior Resident, Urology (1978-79);
Chief Resident, Urology (1979-80)
University of Connecticut Medical Center

1980-83 NIH Immunobiology Research Fellow (Mentor: Lloyd J. Old, MD)
Department of Human Tumor Immunology
Sloan-Kettering Institute for Cancer Research

1982-83 F. C. Valentine Fellow (Mentor: Willet F Whitmore, Jr, MD)
Urologic Oncology Service
Memorial Sloan-Kettering Cancer Center

Positions and Appointments:

Present Bernard and Josephine Chaus Professor of Urologic Oncology,
Director of Urologic Oncology Research
Weill Medical College of Cornell University;

Member (Affiliate), Division of Urology,
Memorial Sloan-Kettering Cancer Center

| Attending Surgeon, [Division](#) of Urology, Memorial Hospital

1992-1999 Assistant Member, Ludwig Institute for Cancer Research,
Memorial Sloan-Kettering Cancer Center

Scientific and Medical Societies:

Fellow, American College of Surgery
American Urological Association
Association for Academic Surgery
Society of Urologic Oncology
American Society of Clinical Oncology
American Association of Cancer Research
Cancer and Leukemia Group B (CALGB), GU Committee, 1989-94
Organizing Committee, IXth International Conference on Monoclonal Antibody
Immunoconjugates, 1993-94
Chair, Medical Research Committee, New York Section, American
Urological Association, 1994-95

Honors and Awards:

- 1969-70 American Cancer Society Pre-doctoral Research Fellowship, Dana-Farber Cancer Center/Harvard Medical School (Mentor: Sidney Farber, M.D.)
- 1973-74 Mosby Scholarship Award, University of Connecticut Medical School
- 1980-83 National Institutes of Health Immunobiology Fellowship, Memorial Sloan-Kettering Cancer Center (Mentor: Lloyd J. Old, M.D.)
- 1982-83 New York Academy of Medicine, Ferdinand C. Valentine Fellow in Urology (Mentor: Willet F. Whitmore, Jr., M.D., Memorial Sloan-Kettering Cancer Center)
- 1983 Society of Surgical Oncology Ewing Research Award
- 1989 Deutsche Gesellschaft fur Urologie (German Urological Association) Prize for Experimental Research
- 1993-02 Prostate Cancer Foundation Research Awards (for each year)
- 2009 Royal College of Surgeons (London) Cutler's Surgical Prize for Innovation

Editorial Boards:

- 2004- Editorial Board, The Prostate
- 2010- Editorial Board, Clinical Genitourinary Cancer

Advisory Boards:

- 1990-2001 Medical Advisory Board, National Kidney Cancer Association
- 1995- BZL Biologics, Inc., Scientific Advisory Board
- 1997-1999 Prostagren, Inc., Scientific Advisory Board
- 2002 Cleveland Clinic Urology, Specialized Program of Research Excellence (SPORE), External Advisory Board
- 2002-2003 Advisory Board, US TOO (NY)

- 2002 Urologic Oncology Branch, National Cancer Institute, External
Advisory Board
- 1995-2005 Kidney Cancer Association, Medical Advisory Board
- 2004-2008 Agensys, Inc., Medical Advisory Board (Chair: Owen Witte, PhD)
- 2007- BIND Biosciences, Inc., Scientific Advisory Board (Chair: R. Langer, PhD)
- 2008 Advisory Board, Bristol Myers - Academic Urologists
- 2009 Advisory Board, Cancer Symposium Planning Committee for Hunter
College Gene Center and Clinical Translational Science Center Symposium
- 2009 Endo Pharmaceuticals, Scientific Advisory Board
- 2010 Medical Advisory Board, Centocor Ortho Biotech, Inc.
- 2012- ADC Therapeutics, sarl, Scientific Advisory Board (Chairman)
- 2014-2015 Avidity Nanomedicines, LLC Scientific Advisory Board (co-Chairs: F. McCormick,
PhD, M. Davis, PhD)

Other Activities:

- 1988 Member, Cancer Clinical Investigation Review Committee (CCIRC)-Ad Hoc
Committee on Urologic Oncology Cooperative Groups, National Institutes of
Health
- 1988 Site Visit Committee, National Cancer Institute
- 1992 Visiting Professor, Japanese Urological Association
- 1994-2003 Cancer Care & Research Committee, New York Hospital-Cornell Medical
Center
- 1996-1998 Human Genetics and Gene Therapy Working Group, New York Hospital-Cornell
Medical Center
- 1996, 1997 Review Committee, Cancer Research Institute's Prostate Cancer Clinical Trials
Program
- 1995, 1997 Reviewer, Ohio Cancer Research Center Grants

- 1996, 2006 Prostate Cancer Foundation Grant Review Committee
- 1998, 1999 Reviewer, Department of Defense-Prostate Cancer Research Program
- 1997 Member, National Cancer Institute Urologic Oncology Branch's Tenure Track Urologic Surgeon Search Committee
- 1999 Consultant in Urology/Urological Oncology, Strang Cancer Prevention Center
- 2003 Visiting Professor, Seminars in Clinical Research, Rockefeller University
- 2003 Visiting Professor, Department of Urology, UCLA School of Medicine
- 2003 Visiting Professor, Johns Hopkins "CaP 2003 New Perspectives"
- 2003 Visiting Professor, Baylor College of Medicine, GU Seminar Series
- 2004-2009 Independent Data Safety Monitoring Committee – Dendreon, Inc.
- 2005 Visiting Professor, VIth European Symposium of the Protein Society, Barcelona, Spain
- 2005– 2007 Member, Institutional Review Board, New York-Presbyterian Hospital
- 2006- Reviewer, US Army Medical Research and Material Command (USAMRMC) Fiscal Year 2006 (FY06) Prostate Cancer Research Program (PCRP) Integration Panel.
- 2007-2011 Weill Cornell Medical College Cancer Center Internal Advisory Committee Member
- 2007-2015 Radioactive Drug Research Committee
- 2008-2012 Member, Search Committee, Director of Research, Urology Department
- 2009, 2010, Reviewer, US Army Medical Research and Material Command
2012 (USAMRMC), Prostate Cancer Program
- 2011 Member, Faculty Advisory Group for WCMC Web Calendar of Events
- 2011-2014 WCMC-Pfizer Centers of Technology Innovation Joint Steering Committee

- 2012-2015 Member, Weill-Cornell Data Safety Monitoring Board
- 2012 WCMC Ad hoc Advisory Subcommittee on Tenure
- 2013, 2014 Chairman, Review Panel, US Army Medical Research and Material Command (USAMRMC), Prostate Cancer Program
- 2013- Internal Advisory Board, WCMC Prostate SPORE
- 2014- Member, Cancer Immunotherapy Guidelines – Genitourinary Malignancies Task Force (CIG-GU): Society for Immunotherapy of Cancer (SITC)
- 2014- Member, Committee on Promotions, WCMC, Dept of Urology
- 2016- Member, Committee of Review, WCMC

BIBLIOGRAPHY

1. Conroy MC, **Bander NH** and Lepow IH: Effect of intradermal injections in the rat of purified proteases from *Streptococcus* and *Serratia marescens*. *Proc Soc Exp Biol Med* 1975; **150**:801-805.
2. **Bander NH**: Comparison of antigen expression of human renal cancer *in vivo* and *in vitro*. *Cancer* 1984; **53**:1235-1239.
3. Cordon-Cardo C, **Bander NH**, Fradet Y, Finstad CL, Whitmore WF Jr, Lloyd KO, Oettgen HF, Melamed MR and Old LJ: Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. *J Histochem Cytochem* 1984; **32**:1035-1040.
4. **Bander NH**, Welt S, Houghton AN, Lloyd KO, Grando R, Yeh S, Whitmore WF Jr, Vaughan ED Jr, Oettgen HF and Old LJ: Radionuclide imaging of human renal cancer with labeled monoclonal antibodies. *Surg Forum* 1984; **35**:652-655.
5. **Bander NH**: Renal cancer: A model system for the study of human neoplasia. *In: Contributions in Oncology*, Riethmuller G, Koprowski H, von Kleist S, (eds). S. Karger, Basel) 1984.
6. Finstad CL, Cordon-Cardo C, **Bander NH**, Whitmore WF Jr, Melamed MR and Old LJ: Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. *Proc Natl Acad Sci USA* 1985; **82**:2955-2959.
7. **Bander NH**, Cordon-Cardo C, Finstad CL, Whitmore WF Jr, Vaughan ED Jr, Oettgen HF, Melamed MR and Old, LJ: Immunohistologic dissection of the human kidney using monoclonal antibodies. *J Urol* 1985; **133**:502-505.
8. **Bander NH**: Study of the normal human kidney and kidney cancer with monoclonal antibodies. *Uremia Invest* 1985; **8**:263-273.
9. Fleischmann J, Heston W, Bauer W, Ratliff T, **Bander NH** and Fair W: Human renal cell carcinoma xenograft morphology, growth and chemosensitivities. *J Urol* 1985; **134**:570-574.
10. **Bander NH** and Cordon-Cardo C: Monoclonal antibody defined markers of human renal cancer. *In: Monoclonal Antibodies to Tumor Markers*, Sell S, Reisfeld R, (eds). Humana Press, Clifton, NJ, 1985.
11. Rosenberg S, **Bander NH** and Herr H: Testis tumors. *In: Current Therapy in Endocrinology*, Krieger D, Bardin W, (eds). BC Decker, Philadelphia, PA 1985.

12. Tolkoff-Rubin NE, Cosimi AB, Delmonico FL, Russell PS, Thompson RE, Piper DJ, Hansen WP, **Bander NH**, Finstad CL, Cordon-Cardo C, Klotz LH, Old and Rubin RH: Diagnosis of tubular injury in renal transplant patients by a urinary assay for a proximal tubular antigen, the adenosine-deaminase-binding protein. *Transplantation* 1986; **41**:593-597.
13. Cordon-Cardo C, Lloyd KO, Finstad CL, McGroarty ME, Reuter VE, **Bander NH**, Old LJ and Melamed MR: Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. *Lab Invest* 1986; **55**:444-454.
14. Sternberg CN, Yagoda A, **Bander NH**, Whitmore WF Jr, Huffman JL, Fleisher M, Melamed MR, Fanucchi MP, Hollander P and Vaughan ED Jr: Phase I/II trial of intravesical methotrexate for superficial bladder tumors. *Cancer Chemother Pharmacol* 1986; **18**:265-269.
15. Tolkoff-Rubin NE, Cosimi AB, Delmonico FL, Russell PS, Thompson RE, Piper DJ, Hansen WP, **Bander NH**, Finstad CL, Cordon-Cardo C, Klotz LH, Old LJ and Rubin RH: Monitoring of renal proximal tubular injury in transplantation with a monoclonal antibody-based assay for the adenosine deaminase-binding protein. *Transplant Proc* 1986; **18**:716-718.
16. **Bander NH**: Monoclonal antibodies. In: *American Urological Association Update*, Ball TP Jr, Novick DE, (eds). AUA Office of Education, Houston, TX 1986.
17. **Bander NH**: Monoclonal antibodies and the diagnosis and treatment of bladder cancer. In: *Bladder Cancer: Future Directions for Treatment*, Yagoda A, (ed). John Wiley & Sons, NY, NY 1986.
18. **Bander NH** and Klotz LH: Tumor immunology: In: *Urologic Oncology*, Graham S Jr, (ed). Raven Press, NY, NY 1986.
19. Cordon-Cardo C, Finstad CL, **Bander NH**, Old LJ and Melamed MR: Immunoanatomic distribution of cytostructural and tissue-associated antigens in the human urinary tract. *Am J Pathol* 1987; **126**:269-284.
20. Tolkoff-Rubin NE, Thompson RE, Piper DJ, Hansen WP, **Bander NH**, Cordon-Cardo C, Finstad CL, Klotz LH, Old LJ and Rubin RH: Diagnosis of renal proximal tubular injury by urinary immunoassay for a proximal tubular antigen, the adenosine deaminase-binding protein. *Nephrol Dialysis Transplant* 1987; **2**:143-1
21. Kantor RRS, **Bander NH**, Finstad CL, Graf LH Jr, Lloyd KO, Old LJ and Albino AP: DNA-mediated gene transfer of a human cell surface 170-kilodalton glycoprotein. Evidence for association with an endogenous murine protein. *J Biol Chem* 1987; **262**:15166-15171.
22. Carter HB, Amberson JB, Bander NH, Badalment R, Gorelick J, Vaughan ED Jr and Whitmore WF Jr: Newer diagnostic techniques for bladder cancer. *Urol Clin N Amer* 1987; **14(4)**: 763-769.

23. **Bander NH**: Monoclonal antibodies: State of the art. *J Urol* 1987; **137**: 603-612.
24. Klotz LH and **Bander NH**: Monoclonal antibodies and urologic oncology: Antigenic expression on genitourinary tumors. *In: Genitourinary Cancer*, Ratliff TL, Catalona WJ, (eds). Martinus Nijhoff Publishers, Boston, MA, 1987.
25. Weir EC, Insogna KL, Brownstein DG, **Bander NH** and Broadus AE: In vitro adenylate cyclase-stimulating activity predicts the occurrence of humoral hypercalcemia of malignancy in nude mice. *J Clin Invest* 1988; **81(3)**: 818-821.
26. **Bander NH**: Continent urinary diversion in the treatment of bladder cancer. *New Developments in Medicine* 1988; **2**: 65-81.
27. Mangin M, Webb AC, Dreyer BE, Posillico JT, Ikeda K, Weir EC, Stewart AF, **Bander NH**, Barton DE, Francke U and Broadus AE: Identification of a complementary DNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. *Proc Natl Acad Sci USA* 1988; **85**: 597-601.
28. Sternberg C, Yagoda A, Scher H, Watson R, Herr H, Morse M, Sogani P, Vaughan ED Jr, **Bander NH**, Weiselberg L, Geller N, Hollander P, Lipperman R, Fair WR and Whitmore WF Jr: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. *J Urol* 1988; **139**: 461-469.
29. Ikeda K, Mangin M, Dreyer B, Webb A, Posillico J, Stewart A, **Bander NH**, Weir E, Insogna K and Broadus AE: Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy. *J Clin Invest* 1988; **81**: 2010-2014.
30. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, **Bander NH**, Geller N, Fair WR and Whitmore WF Jr: Chemotherapeutic management of invasive bladder carcinoma. *Eur Urol* 1988; **14** (suppl): 19-20.
31. **Bander NH**, Finstad CL, Cordon-Cardo C, Ramsawak RD, Vaughan ED Jr, Whitmore WF Jr, Oettgen HF, Melamed MR and Old LJ: Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets of renal cell carcinomas. *Cancer Res* 1989; **49**: 6774-6780.
32. Sternberg C, Yagoda A, Scher HI, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, **Bander NH** et al.: M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. *Cancer* 1989; **64**: 2448-2458.

33. Nanus DM, Ebrahaim SAD, **Bander NH**, Real FX, Pfeffer LM, Shapiro JR and Albino AP: Transformation of human kidney proximal tubule cells by *ras*-containing retroviruses. Implications for tumor progression. *J Exp Med* 1989; **169**: 953-972.
34. Wang JCL, Walle A, Novogrodsky A, Suthanthiran M, Silver RT, **Bander NH**, Rubin AL and Stenzel KH: A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion of interleukin-2. *J Clin Oncol* 1989; **7**: 1885-1891.
35. Yagoda A and **Bander NH**: Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. *Urol Int* 1989; **44**: 338-345.
36. **Bander NH**: ed. Renal cell carcinoma. In: *Seminars in Urology*, vol 7, no 3, WB Saunders, Philadelphia, PA, 1989.
37. Ebert T and **Bander NH**: Kidney-derived cell lines. *Seminars in Urology* 1989; **7**:247-251.
38. **Bander NH**: Monoclonal antibodies to renal cancer antigens. *Seminars in Urology* 1989; **7**: 264-270.
39. **Bander NH**: Ureteral stent for nonrefluxing, continent urinary diversions reduces complications and hospitalization for patients. *Urol* 1990; **35**: 64-67.
40. Nanus DM, Mentle IR, Motzer RJ, **Bander NH** and Albino AP: Infrequent *ras* oncogene point mutations in renal cell carcinoma. *J Urol* 1990; **143**: 175-178.
41. Nanus DM, Pfeffer LM, **Bander NH**, Bahri S and Albino AP: Anti-proliferative and anti-tumor effect of alpha-interferon in renal carcinoma: correlation to the expression of kidney associated differentiation glycoprotein. *Cancer Res* 1990; **50**: 4190-4194.
42. Ebert T, **Bander NH**, Finstad CL, Ramsawak RD and Old LJ: Establishment and characterization of renal cancer and normal kidney cell lines. *Cancer Res* 1990; **50**: 5531-5536.
43. Rettig WJ, Triche TJ and **Bander NH**: Somatic cell genetic analysis of human cell surface antigens 5.1H11 and F35/9 (gp45). *Genomics* 1990; **6**: 178-183.
44. Libby DM, **Bander NH**, Altorki NK, Gold J, Pitts WR Jr and Frankel SS: Simultaneous pulmonary and renal malignancy. *Chest* 1990; **98**: 153-156.
45. Kerr L, Huntcoon C, Donohue J, Leibson PJ, **Bander NH**, Ghose T, Luner SJ, Vessella R and McKean DJ: Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells in *in vitro* activated lymphocytes. *J Immunol* 1990; **44**: 4060-4067.
46. **Bander NH**: Monoclonal antibodies to renal cancer antigens. *Eur Urol* 1990; **18**: 10-12.

47. Ebert T and **Bander NH**: Immunodiagnosis of renal cancer. *In: Immunodiagnosis of Cancer*, Mercer DW, Herberman RB, (eds). Marcel Dekker, New York, NY 1990
48. Sheinfeld J, Cordon-Cardo C and **Bander NH**: Immunodiagnosis of bladder cancer. *In: Immunodiagnosis of Cancer*, Mercer DW, Herberman RB, (eds). Marcel Dekker, New York, NY 1990.
49. Ebert T, Ackerman R and **Bander NH**: Biologische marker beim nierenzellkarzinom. *Urologie* 1990; **29**: 65-70.
50. Gulmi FA and **Bander NH**: Managing carcinoma in situ of the bladder. *Contemp Urol* 1990; **1**: 45-52.
51. **Bander NH**: Initial results with a slightly modified Koch pouch. *Urol* 1991; **37**:100-105.
52. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, **Bander NH** and Gansbacher B: Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. *Cancer Res* 1992; **52**: 6229-6236.
53. **Bander NH**, Gastl G, Nanus DM, Pfeffer LM, Finstad CL and Albino AP: Anti-proliferative and anti-tumor effect of a-interferon in renal cell carcinoma: Correlation with the expression of a kidney associated differentiation glycoprotein. *In: Basic and Clinical Research on Renal Cell Carcinoma*, Staehler G, Pomer S, (eds). Springer-Verlag, Heidelberg, Germany 1992.
54. Oosterwijk E, **Bander NH**, Divgi CR, Welt S, Wakka JC, Finn R, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. *J Clin Oncol* 1993; **11**: 738-750.
55. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, **Bander NH** and Rubin SC: High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. *Brit J Haematol* 1993; **83**: 433-441.
56. Gastl G, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen N, Albino AP and **Bander NH**: Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. *Int J Cancer* 1993; **55**: 96-101.
57. Nanus DM, Engelstein D, Gastl GA, Gluck L, Vidal MJ, Morrison M, Finstad CL, **Bander NH** and Albino AP: Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. *Proc Natl Acad Sci USA* 1993; **90**: 7069-7073.
58. Holt EH, Vasavada RC, **Bander NH**, Broadus AE and Philbrick WM: Region-specific methylation of the parathyroid hormone-related peptide gene determines its expression in human renal carcinoma cell lines. *J Biol Chem* 1993; **268**: 20639-20645.

59. Gastl G, **Bander NH**, Frick J, Huber C and Aulitzky W: Immunotherapie des metastasierten nierenzellkarzinomas mit rekombinantem interferon-gamma. *In: Immunotherapie in der Uroonkologie*, Rubben H, Goepel M, Schmitz-Drager B, (eds). Springer-Verlag, Heidelberg, Germany 1993.
60. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh F-M, Lubensky I, Duan D-S R, Florence C, Pozzatti R, Walther MM, **Bander NH** et al.: VHL tumor suppressor gene mutations in renal cell carcinoma tumorigenesis. *Nature Genet* 1994; **7**: 85-90.
61. **Bander NH**: Current status of monoclonal antibodies for imaging and therapy of prostate cancer. *In: Seminars in Oncology*, Scher H., (ed). WB Saunders, New York, NY 1994; **21**.
62. Berger MF, Oosterwijk E, **Bander NH**, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, van Fleuren G, Oettgen HF and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. *In: Biology of Renal Cell Carcinoma*, Bukowski RM, Finke JH, Klein EA, (eds). Springer-Verlag, New York, NY 1995.
63. **Bander NH**: Immunology of renal cancer. *In: Comprehensive Textbook of Genitourinary Oncology*, Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, (eds). Williams & Wilkins, Philadelphia, PA 1995.
64. Kinouchi T, **Bander NH** and Kotake T: Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement-dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity. *J Urol* 1995; **154**: 288-292.
65. Aoyagi T, **Bander NH**: Cytotoxicity of gallium nitrate *in vitro* using bladder cancer cells. *Int J Urol* 1995; **2(5)**: 288-294.
66. Gastl G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W and **Bander NH**: MHC Class I and Class II expression in renal cell carcinoma and modulation by interferon-gamma. *J Urol* 1996; **155**: 361-367.
67. Motzer RJ, **Bander NH** and Nanus DM: Renal cell carcinoma. *N Engl J Med* 1996; **335**: 865-875.
68. Shemtov MM and **Bander NH**: Immunologic approaches to genitourinary malignancies. *In Campbell's Urology Update* (Patrick C Walsh, Alan B Retik, Thomas A Stamey, E Darracott Vaughan and Alan J Wein, (eds) Philadelphia, PA. **20**,1996.
69. McKiernan JM, Buttyan R, **Bander NH**, Stifelman MD, Katz AE, Chen M-W, Olsson CA and Sawczuk IS: Expression of the tumor-associated gene MN; a potential biomarker for human renal cell carcinoma. *Cancer Res* 1997; **57**: 2362-2365.

70. Schmetter BS, Habicht KK, Lamm DL, Morales A, **Bander NH**, Grossman HB, Hanna Jr MG, Silberman SR and Butman BT: A multicenter trial evaluation of the Aura-Tek FDP test for detection and monitoring of bladder cancer. *J Urol* 1997; **158**: 801-805.
71. Motzer RJ, Bander NH and Nanus DM: Letter to the Editor. *N Engl J Med* 1997; **336**: 810-811.
72. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B and **Bander NH**: Monoclonal antibodies to the extracellular domain of prostate specific membrane antigen also react with tumor vascular endothelium. *Cancer Res* 1997; **57**: 3629-3634.
73. **Bander NH**, Yao D, Liu H, Chen Y-T, Steiner M, Zuccaro W and Moy P: MHC Class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. *The Prostate* 1997; **33**: 233-239.
74. Oosterwijk E, **Bander NH**, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF, and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. *Classic Papers and Current Comments* 1997; **2**: 331-344.
75. **Bander NH**, Cordon-Cardo C, Finstad CL, Whitmore WF Jr., Vaughan ED Jr., Oettgen HF, Melamed M, and Old LJ: Summary of Immunohistologic Dissection of the Human Kidney Using Monoclonal Antibodies. *Seminars in Urol Oncol* 1997; **15**(2): 123-130.
76. Nanus DM, Bogenrieder T, Papandreou CN, Finstad CL, Lee A, Vlamis V, Motzer RJ, **Bander NH**, Albino AP, and Reuter VE: Aminopeptidase A expression and enzymatic activity in primary human renal cancers. *Int J Oncology* 1998; **13**(2): 261-267.
77. Liu H, Rajasekaran A.K., Moy P., Xia Y., Kim S., Navarro V., Rahmati R., and **Bander NH**: Constitutive and Antibody-Induced Internalization of Prostate Specific Membrane Antigen. *Cancer Res* 1998; **58**: 4055-4060.
78. Divgi C.R., **Bander NH**, Scott A.M., O'Donoghue, Sgouros G, Welt S., Finn R.D., Morrissey F., Capitelli P., Williams J.M., Deland D., Nakhre A., Oosterwijk E., Gulec S., Graham M.C., Larson S.M., Old L.J.: Phase I/II radioimmunotherapy trial with iodine-131 labeled monoclonal antibody (mAb) G250 in metastatic renal carcinoma. *Clin Cancer Res* 1998;**4**: 2729-2739 .
79. Prewett M, Rothman M, Waksal H, Feldman M, **Bander NH**, and Hicklin D.J.: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. *Clin Cancer Res* 1998; **4**: 2957-2966.
80. Ebert T, Anastasiadis A, **Bander NH**: Renal Cell Cancer in *Human Cell Culture* JR.W. Masters and B. Palsson (eds). Kluwer Academic Publishers 1999.

81. Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski R, Tubbs R, Hsi ED, **Bander, NH**, Novick AC, and Finke JH: Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. *Clin Cancer Res* 1999; **5**: 1219-1229.
82. Kolenko V, Uzzo RG, Bukowski R, Bander NH, Novick AC, Finke JH: Dead or dying: Necrosis vs. apoptosis in caspase deficient human renal cell carcinoma. *Cancer Res*, 1999,**59**: 2838-2842.
83. Chang SS, Reuter VE, Heston WDW, **Bander NH**, Grauer LS, and Gaudin PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. *Cancer Res* 1999; **59**: 3192-3198.
84. Gong MC, Latouche JB, Krause A, Heston WDW, **Bander NH** & Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. *Neoplasia* 1999; **1(2)**: 123-127 .
85. Rajasekaran SA, Ball WJ Jr, **Bander NH.**, Liu H, Pardee JD, and Rajasekaren AK: Reduced expression of β -subunit of Na,K-ATPase in human clear-cell renal cell carcinoma. *J Urology*, 1999; **162**: 574-580.
86. Shirakawa T, Gardner TA, Ko S-C, **Bander N**, Woo S, Gotoh A, Kamidono S, Chung LWK and Kao C: Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. *J Urology* 1999; **162**: 949-954.
87. Scanlan MJ, Gordan JD, Williamson B, Stockert E, **Bander NH**, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT and Old LJ: Antigens recognized by autologous antibody in patients with renal-cell carcinoma. *Int J Cancer* 1999, **83(4)**: 456-464.
88. Chang SS, Bander NH, Heston WDW: Monoclonal Antibodies: Will they become an integral part of the evaluation and treatment of prostate cancer-focus on prostate-specific membrane antigen. *Current Opinion In Urology* 1999; **9**: 391-395.
89. **Bander NH**: Monoclonal antibodies for imaging and therapy of prostate cancer. Klein E (ed). *Management of Prostate Cancer*. Humana Press, Totowa, NJ: 1999.
90. Gong MC, Chang SS, Sadelain M, **Bander NH**, Heston WDW: Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate cancer. *Cancer Metastasis Rev* 1999; **18**: 483-90.

91. McKiernan JM, Buttyan R, **Bander NH**, de la Taille A, Stifelman MD, Emanuel ER, Bagiella E, Rubin MA, Katz AE, Olsson CA, Sawczuk IS: The detection of renal cancer cells in the peripheral blood via an enhanced RT-PCR assay for MN/CA9. *Cancer*, 1999; **86(3)**: 492-497.
92. **Bander NH**: Monoclonal antibodies in the diagnosis and treatment of renal cancer. Vogelzang NJ et al (eds). *Comprehensive Textbook of Genitourinary Oncology, Second Edition*, Lippincott Williams & Wilkins, Philadelphia, PA, 1999.
93. Oosterwijk E, Divgi CR, Steffens MS and **Bander NH**: Monoclonal antibodies in advanced renal cell carcinoma. Bukowski RM and Novick AC (eds). *Renal Cell Carcinoma – Molecular Biology, Immunology, and Clinical Management*, Humana Press, Totowa, NJ: 2000.
94. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D and **Bander NH**: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. *Cancer Res*, 2000; **60(18)**: 5237-5243.
95. McDevitt MR, Barendswaard E, Ma D, Curcio MJ, Lai L, Sgouros G, Ballangrud AM, Yang W-H, Finn RD, Geerlings MW Jr, Brechbiel MW, **Bander NH**, and Scheinberg DA: An Alpha-particle emitting antibody ([²¹³Bi]J591) for radioimmunology of prostate cancer. *Cancer Res*. 2000; **60**: 6095-6100.
96. Gong MC, Chang SS, Watt F, O'Keefe DS, Bacich DJ, Uchida A, **Bander NH**, Reuter VE, Gaudin PB, Molloy PL, Sadelain M, Heston WD: Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. *Mol Urol* 2000 ;**4(3)**: 217-222.
97. de la Taille A; Cao Y, Sawczuk IS, Nozemu T, d'Agati V, McKiernan JM, Bagiella E, Buttyan R, Burchardt M, Olsson CA, **Bander N**, Katz AE: Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion. *Cancer Detect Prev* 2000, **24(6)**: 2008-2014.
98. Rajasekaran SA, Palmer LG, Ball WJ Jr, **Bander NH**, Alejandro Peralta Soler and Rajasekaran AK: Na,K-ATPase β -subunit is required for epithelial polarization, suppression of invasion and cell motility. *Mol Biol Cell* 2001; **12**: 279-295.
99. Goldsmith SJ, **Bander NH**: Prostate cancer: Monoclonal Antibody Therapy. Khalkhali I, Maublant JC, Goldsmith SJ (eds). *Nuclear Oncology: Diagnosis and Therapy*. Lippincott Williams & Wilkins, Philadelphia, 2001.
100. Ballangrud AM, Yang W-H, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, **Bander NH**, Scheinberg DA and Sgouros G: Response of LNCaP spheroids after treatment with an α -particle emitter (²¹³Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). *Cancer Res* 2001; **61**: 2008-2014.

101. Divgi CR, Oosterwijk E, **Bander NH**, Welt S, Larson SM, Old L: Renal Carcinoma: Monoclonal Antibody Therapy. Khalkhali I, Maublant JC, Goldsmith SJ (eds). Nuclear Oncology: Diagnosis and Therapy. Lippincott Williams & Wilkins, Philadelphia, 2001.
102. Uzzo RG, Kolenko V, Froelich CJ, Tannenbaum C, Molto L, Novick AC, **Bander NH**, Bukowski R and Finke JH: The T cell death knell: Immune-mediate tumor death in renal cell carcinoma. *Clin Cancer Res* 2001; **7**: 3276-3281.
103. Belldegrun A, **Bander NH**, Lerner SP, Wood DP, Pantuck AJ: Society of Urologic Oncology Biotechnology Forum: New Approaches and Targets for Advanced Prostate Cancer. *J Urol* 2001; **166**: 1316-1321.
104. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank K, Wu K, Pellegrini V, Curcio MJ, Miederer M, **Bander NH**, Scheinberg, DA.: Tumor Therapy with Targeted Atomic Nano-Generators. *Science* 2001; **294**: 1537-1540.
105. Li Y, Tian Z, Rizvi S, **Bander NH**, Allen BJ: In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. *Prostate Cancer and Prostatic Dis* 2002; **5**: 36-46.
106. Smith Jones MP, Vallabhajosula S, Navarro V, Goldsmith SJ and **Bander NH**: 90Y-huJ591 mAb specific to PSMA: radioimmunotherapy (RIT) studies in nude mice with prostate cancer LNCaP tumor. *Eur J Nucl Med* 2002; **8**: 951.
107. Christiansen JJ, Rajasekaran SA, Moy P, Butch A, Goodglick, Gu Z, Reiter R, **Bander NH**, Rajasekaran AK: Polarity of prostate specific membrane antigen, prostate stem cell antigen and prostate specific antigen in prostate tissue in a cultured epithelial cell line. *The Prostate* 2003; **55**: 9-19.
108. Anilkumar G, Rajasekaran S, Wong S, Hankinson O, Bander NH and Rajasekaran AK: Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALAdase activity. *Cancer Res*, 2003: **63**: 2645-2648.
109. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ and **Bander NH**: Radiolabeled monoclonal antibodies specific to the extra-cellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. *J Nuc Med*, 2003; **44**: 610-617.
110. Nanus D, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ and **Bander NH**: Clinical use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen. *J Urol*, 2003:**170**: S84-S89.
111. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, **Bander NH**, Rajasekaran AK: A novel cytoplasmic tail MXXXL motif mediates the internalization and

lysosomal targeting of prostate specific membrane antigen. *Molecular & Cell Biology*, 2003;**14**: 4835-4845.

112. **Bander, NH**, Trabulsi E, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM and Goldsmith SJ: Targeting Metastatic Prostate Cancer with Radiolabeled Monoclonal Antibody J591 in the Extracellular Domain of Prostate Specific Membrane Antigen. *J Urol*, 2003; **170**: 1717-1721.

113. **Bander, NH**, Nanus, D.M., Milowsky, M.I., Kostakoglu, L., Vallabahajosula, S., and Goldsmith, S.J.: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate specific membrane antigen (PSMA). *Seminars in Oncology*, 2003; **30**: 667-676.

114. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W., **Bander NH**, and Rajasekaran AK.: A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen. *Mol Bio Cell* 2003; **14**: 4835-4845.

115. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ and Bander NH: Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice. *The Prostate*, 2004; **58**: 145-155.

117. Milowsky M.I., Nanus D.M., Kostakoglu L., Vallabhajosula S, Goldsmith S.J., and **Bander NH**: Phase I Trial Results of ⁹⁰Yttrium Labeled Anti-Prostate Specific Membrane Antigen Monoclonal Antibody J591 in the Treatment of Patients with Recurrent Prostate Cancer. *J Clin Onc*, 2004; **22**: 2522-2531.

118. Patri AK, Myc A, Beals, J, Thomas TP, **Bander NH**, Baker JR: Synthesis and *in vitro* testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. *Bioconjug Chem*, 2004; **15**: 1174-1181.

119. Konishi S, Hamacher K, Vallabhajosula S, Kothari P, Bastidas D, **Bander NH**, Goldsmith S: Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method? *Cancer Biother Radiophar* 2004; **19**: 706-715.

120. Kelly JD, Dai J, Eschwege P, Goldbreg JS, Duggan BP, Williamson KE, **Bander NH**, Nanus DM: Down-regulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas. *Br J Cancer* 2004; **91**: 164-170.

121. Christiansen JJ, Rajasekaran SA, Weimbs T, Gopalakrishna A, **Bander NH** and Rajasekaran AK: N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. *Mol.Bio.Cell*, 2005; **4**:1-11.

122. **Bander NH:** Editorial “Novel Therapy for PSA Progression in Absence of Imagable Disease Following Local Therapy. Cummings, K., (ed). *Management of Prostate Cancer: Advances and Controversies*. Marcel Dekker, Inc, New York, NY: 2005.
123. **Bander NH,** Milowsky M.I., Nanus D.M., Kostakoglu L., Vallabhajosula S, and Goldsmith S.J.: Phase I Trial Results of ¹⁷⁷Lutetium Labeled j591, A Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer. *J Clin Onc*, 2005; **23**:4591-4601.
124. Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowsky MI, Nanus DM, **Bander NH** and Goldsmith SJ: Pharmacokinetics and Biodistribution of ¹¹¹In and ¹⁷⁷Lu Labeled J591 Antibody Specific to Prostate Specific Membrane Antigen Prediction of ⁹⁰Y-J591 Radiation Dosimetry Based on ¹¹¹In and ¹⁷⁷Lu. *J Nuc Med*, 2005; **46**:634-641.
125. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowsky MI, Nanus DM and **Bander NH:** Prediction of Myelotoxicity Based on Bone Marrow Radiation Absorbed Dose: Radioimmunotherapy Studies using ⁹⁰Y and ¹⁷⁷Lu labeled J591 Antibodies Specific to Prostate Specific Membrane Antigen (PSMA). *J Nuc Med*, 2005; **46**:850-858.
126. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM and **Bander NH:** Radioimmunotherapy of Prostate Cancer Using ⁹⁰Y and ¹⁷⁷Lu Labeled J591 Monoclonal Antibodies: Effect of Dose Fractionation and Multiple Treatments on Myelotoxicity. *Clin Cancer Res*, 2005; **11**:7195s-7200s.
127. Ross JS, Gray KE, Webb I, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Milowsky MI, **Bander NH:** Antibody-Based Therapeutics: Focus on Prostate Cancer. *Cancer & Metast Rev*, 2005; **24**:517-533.
128. **Bander, N.H.:** Technology insights: monoclonal antibody imaging of prostate cancer. *Nat Clin Pract Urol*, 2006;**3**:216-225.
129. David KA, Milowsky MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Nanus DM, **Bander NH.:** Clinical Utility of Radiolabeled Antibodies in Prostate Cancer. *Clin Genitourin Cancer*, 2006;**4**:249-256.
130. Ross JS, Gray, KE, Webb I, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Milowsky MI, **Bander NH:** PSMA and Other Cell Surface Protein Targets For Antibody-Based Immunotherapy for Prostate Cancer, Ross J (ed). *Molecular Oncol of Prostate Cancer*. Jones & Bartlett, Boston, MA., 2006.

131. Christiansen J J, Weimbs T, **Bander N**, and Rajasekaran A K: Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents on t-SNARE mediated apical targeting of prostate specific membrane antigen. *Mol Cancer Ther*, 2006; **5**:2468-2473.
132. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Ross JS, and **Bander NH**.: Vascular Targeted Therapy with Anti-PSMA Monoclonal Antibody J591 in Patients with Advanced Solid Tumor Malignancies. *J Clin Onc*, 2007; **25**:540-547.
133. Goodman OB, Barwe SP, McPherson P, Vasko A-J, Keen JH, Nanus DM, **Bander NH** and Rajasekaran AK: Interaction of prostate specific membrane antigen with clathrin and adaptor protein complex-2. *Intl J Oncology*, 2007; **31**:1199-1203.
134. **Bander, NH**. Invited editorial comment to: Urba, WJ, et al: Treatment of Biochemical Recurrence of Prostate Cancer with Granulocyte-Macrophage Colony-Stimulating Factor-Secreting, Allogeneic, Cellular Immunotherapy. *J Urol* 2008, **180**:2017-2018.
135. Wang AZ, Bagalkot V, Vasilliou C, Gu F, Alexis F, Zhang L, Shaikh M, Yuet K, Cima M, Langer R, Kantoff PW, **Bander NH**, Jon S, Farokhzad OC: Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy. *ChemMedChem*, 2008, **3**:1311-5.
136. **Bander, NH**. Invited editorial comment to: Mouraviev, V, et al, Use of ¹¹¹In-Capromab Pendetide Immunoscintigraphy to Image Localized Prostate Cancer Foci Within the Prostate Gland. *J Urol*, 2009, **182**:947-948.
137. Kuroda K, Liu H, Guo M, Navarro V, **Bander NH**: Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA Surrogacy. *The Prostate*, 2009 **19**:1579-85.
138. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, Ofner D, Zelger B, Ensinger C, Yang XJ, Geley S, Margreiter R and **Bander NH**: Prostate Specific Membrane Antigen Expression in the Neovasculature of Gastrointestinal Cancers. *Hum Pathol*, 2009, **40**:1754-61.
139. **Bander NH**, Vallabhajosula S, Goldsmith SJ, Tagawa ST, Nanus DM: Radioimmunotherapy of Prostate Cancer: Targeting Prostate-Specific Membrane Antigen. Tod W Speer (ed.). *Targeted Radionuclide Therapy*. Lippincott Williams & Wilkins, Philadelphia, PA, 2010.
140. Kuroda K, Liu H, Kim S, Guo M, Navarro V, **Bander NH**: Saporin Toxin-Conjugated Monoclonal Antibody Targeting Prostate Specific Membrane Antigen Has Potent Anticancer Activity. *The Prostate*, 2010,**70**:1286-1294.
141. Gleghorn JP, Pratt ED, Denning D, Liu H, **Bander NH**, Tagawa ST, Nanus DM, Paraskeva PK, and Kirby BJ. Capture of circulating tumor cells from whole blood of prostate cancer patients

using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. *The Royal Soc of Chem*, LAB CHIP, 2010, **10**:27-29. Epub 2009 Nov 16.

142. Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith S, Osborne J, Matulich D, Petrillo, Parmar S, Selzer J, Nanus DM, **Bander NH**: Anti-Prostate Membrane Specific Antigen-based Radioimmunotherapy for Prostate Cancer. *Cancer*, 2010, **116**:1075-1083.

143. Holland JP, Divilov V, **Bander NH**, Smith-Jones PM, Larson SM, Lewis JS. ^{89}Zr -DFO-J591 for immunoPET imaging of prostate-specific membrane antigen (PSMA) expression in vivo. *J Nucl Med* **51**:1293-1300; e-published July 21,2010.

144. Wang AZ, Yuet K, Zhang L, Gu FX, Huynh-Le M, Radovic-Moreno AF, Kantoff PW, Bander NH, Langer R and Farokhzad OC. ChemRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. *Nanomedicine*, 2010, **5**:361-368.

145. Wernicke,G, Edgar MA, Moy P, Liu H, Salerno P, **Bander NH**, Gutin PH. Prostate-Specific Membrane Antigen as a Potential Novel Vascular Target for Treatment of Glioblastoma Mutiforme. *Archives of Pathology & Laboratory Medicine*, 2011, **135**:1486-1489.

146. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, **Bander NH**, Larson SM, and Sawyers CL. Non-invasive measurements of androgen receptor signaling with ^{64}Cu -J591, a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen *PNAS* 2011,**108**:9578-9582; e-published ahead of print May 13, 2011. PMID: 21606347

147. Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, **Bander NH**, Lewis JS, Grimm J: Targeting the internal epitope of prostate-specific membrane antigen with ^{89}Zr -7E11 immuno-PET. *J Nucl Med*. 2011 Oct; 52(10):1608-15. doi: 10.2967/jnumed.111.092098. Epub 2011 Sep 9. PMID: 21908391

148. Nakajima T, Mitsunaga M, **Bander NH**, Heston WD, Choyke PL, Kobayashi H. Targeted, Activatable, In Vivo Fluorescence Imaging of Prostate Specific Membrane Antigen (PSMA)-positive Tumors Using the Quenched Humanized J591 Antibody-Indocyanine Green (ICG) Conjugate. *Bioconjug Chem*, 2011,**22**:1700-1705. . E-pub July, 2011: PMID: 21740058

149. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, **Bander, NH**, Nanus DM, and Giannakakou P. Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer. *Cancer Res*, 2011, **71**:6019-29. E-pub 2011 Jul 28. PMID: 21799031.

150. Santana SM, Liu H, **Bander NH**, Gleghorn JP, Kirby BJ. Immunocapture of Prostate Cancer Cells by use of Anti-PSMA Antibodies in Microdevices. *Biomed Microdevices*, 2011, **14**:401-407. E-pub December, 2011:PMID:22143878.

151. Hrkach J, Von Hoff D, Ali M, Andrianova E, Auer J, Campbell T, DeWitt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retriarajan B, Sabnis AA, Schnipper E, Song J, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, **Bander NH**, Sweeney C, Farokhzad OC, Langer R and Zale S. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile. *Science Translational Medicine*, 2012, **4**:128ra39.
152. Haffner MC, Laimer J, Chaux A, Schafer G, Obrist P, Brunner A, Kronberger IE, Laimer K, Gurel B, Koller B, Seifarth C, Beier U, Zeiger B, Klocker H, Rasse M, Doppler W **and Bander NH**. High expression of PSMA in the tumor-associated neovasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. *Modern Pathology*, 2011, 1-7.
153. Crowley MJ, Scognamiglio T, Liu Y-F, Kleiman DA, , Beninato T, Aronova A , Liu H, Jhanwar YS, **Bander NH**, Zarnegar R, Elemento, O and Fahey TJ III. An Investigation of Vascular Markers as a Potential Therapeutic Target in Adrenocortical Carcinoma. Manuscript submitted.
154. Kirby BJ, Jodari M, Loftus MS, Pratt ED, Chanel-Vos C, Gakhar G, Gleghorn JP, Santana SM, Liu H, Smith JP, Tagawa ST, **Bander NH**, Nanus DM, Giannakakou P, Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device. *PLoS One*, 2012;7(4):e35976. Epub 2012 Apr 27. Erratum in: *PLoS One*. 2012;7(7): doi/10.1371/annotation/9d3d22ed-dc5a-4484-9254-1584864f4aac. PMID: 22558290
155. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Witner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, **Bander NH**, Wu C-L, Sequiat LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. *Cancer Discovery* **2**: 1-9. 2012. PMID: 23093251
156. Tagawa S, Osborne J and **Bander NH**. PSMA-based Diagnostics. Tewari A (ed). *Comprehensive Textbook of Prostate Cancer*. Springer, New York, NY, 2012.
157. Goldsmith SJ, Tagawa S, Vallabhajosula S, Nilolopoulou A, Lipai I, Nanus DM, **Bander NH**. Radioimmunotherapy of Prostate Carcinoma. C. Aktolun and SJ Goldsmith (eds.). *Nuclear Medicine Therapy: Principles and Clinical Applications*. Springer, New York, NY 2013.
158. Valencia PM, Pridgen EM, Perea B, Gadde S, Sweeney C, Kantoff PW, **Bander NH**, Lippard SJ, Langer R, Karnik R, Farokhzad OC. Synergistic Cytotoxicity of Irinotecan and Cisplatin in Dual-Drug Targeted Polymeric Nanoparticles. *Nanomedicine (Lond)*. 2013 May;8(5):687-98. doi: 10.2217/nnm.12.134. Epub 2012 Oct 17. PMID: 23075285
159. **Bander NH**, Czuczman MS, Younes A. Antibody-drug conjugate technology development for hematologic disorders. *Clin Adv Hematol Oncol*. 2012 Aug;10 (8 Suppl 10):1-16. PMID:23072775

160. Huang C, Santana SM, Liu H, **Bander NH**, Hawkins BG, Kirby BJ. Characterization of a hybrid dielectrophoresis and immunocapture microfluid system for cancer cell capture. *Electrophoresis*, 2013 Aug 8. doi: 10.1002/elps.201300242. [Epub ahead of print] PMID:23925921
161. Wernicke G, Greenwood EA, Christos PJ, Chao KSC, Liu H, **Bander NH**, Shin SJ. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. *APMIS*, 2013 Dec 5. doi: 10.1111/apm.12195. [Epub ahead of print]. PMID: 24304465
162. **Bander NH**. Antibody–Drug Conjugate Target Selection: Critical Factors. *Methods Mol Biol*. 2013;1045:29-40. doi: 10.1007/978-1-62703-541-5_2. PMID:23913139
163. Tagawa ST, Akhtar NH, Nikolopoulou A, Kaur G, Robinson B, Kahn R, Vallabhajosula S, Goldsmith SJ, Nanus DM and **Bander NH**. Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer. *Frontiers in Radiation Oncology*, 2013 in press.
164. Huang C, Liu H, **Bander NH**, Kirby BJ. Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system. *Biomedical Devices*. 2013 Jun 27. [Epub ahead of print] PMID:23807279
165. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, **Bander NH**, Nanus DM. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. *Clin Cancer Res*. 2013 Sep 15;19(18):5182-91. doi: 10.1158/1078-0432.CCR-13-0231. Epub 2013 May 28. PMID: 23714732
166. Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, **Bander NH**, Scherr DS. A Prospective Pilot Study of 89Zr-J591/PSMA Positron Emission Tomography (PET) in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. *J Urol*. 2013 Oct 14. doi:pii: S0022-5347(13)05648-6. 10.1016/j.juro.2013.10.041. [Epub ahead of print] PMID: 24135437
167. Gakhar G, Navarro V, Jurish M, Lee GY, Tagawa ST, Akhtar NH, Seandel M, Geng Y, Liu H, **Bander NH**, Giannakakou P, Christos PJ, King MR, Nanus DM. Circulating Tumor Cells from Prostate Cancer Patients Interact with E-Selectin under Physiologic Blood Flow. *PLOS ONE*. December 27, 2013. DOI:10.1371/journal.pone.0085143 PMID:24386459
168. Gakhar, G., **Bander, N. H.**, Nanus, D. M. *In vitro* Method to Observe E-selectin-mediated Interactions Between Prostate Circulating Tumor Cells Derived From Patients and Human Endothelial Cells. *J. Vis. Exp.* 2014 May 15 (87), e51468, doi:10.3791/51468. PMID: 24894373

169. Klute, K, Nackos, E, Tasaki Shinsuke, Nguyen DP, **Bander NH**, Tagawa ST. Microtubule inhibitor based antibody-drug conjugates for cancer therapy. *Onco Targets Ther.* 2014 Dec 3:2227-2236. PMID: 25506226
170. Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack, JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda M, Smith-Jones PM, Weber WA, **Bander NH**, Scher HI, Morris MJ, Larson SM. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. *Eur J Nucl Med Mol Imaging.* 2014 Nov 21; 41 (11); 2093-105.PMID: 25143071
171. Chakravarty D, Sboner A, Nair S, Giannopoulou E, Li R, Hennig S, Mosquera J M, Pauwels J , Park K, Kossai M, MacDonald T, Fontugne J, Erho N, Vergara I, Ghadessi M, Davicioni E, Jenkins R, Palanisamy N, Chen Z, Nakagawa S, Hirose T, **Bander NH**, Beltran H, Fox A, Elemento O, and Rubin M. The Estrogen receptor alpha regulated lncRNA NEAT1 is a critical modulator of prostate cancer. *Nature Commun* 2014 Nov 21; 5:5383 doi: 10.1038/ncomms6383 PMID: 25415230
172. Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, **Bander NH**, Goldsmith SJ. Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTA-huJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. *Curr Radiopharm.* 2015 Mar 13. PMID: 25771365
173. Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gonen M, Smith-Jones P, **Bander NH**, Scher HI, Larson SM, Morris MJ. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. *EJNMMI Res.* 2015 Apr 29;5:28; PMID: 25984435
174. Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gonen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne J, Lewis JS, Reuter V, Weber WA, **Bander NH**, Scher HI, Larson SM, Morris MJ. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. *Clin Cancer Res.* 2015 Jul 14;PubMed PMID: 26175541
175. Wernicke AG, Kim S, Liu H, **Bander NH**, Pirog EC. Prostate-Specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecological Malignancies: Implications for PSMA-targeted Therapy. *Appl Immunohistochem & Molec Morphol*, 2016 Feb. [Epub ahead of print] PMID:26862945
176. Crowley MJP , Scognamiglio T, Liu Y, Kleiman DA, Beninato T, Aronova A, Liu H, Jhanwar YS, **Bander NH**, Zarnegar R, Elemento O, and Fahey TJ III. Prostate Specific Membrane Antigen is a Potential Anti-Angiogenic Target in Adrenocortical Carcinoma. *J Clin Endocrinol Metab.* 2016 Mar;101(3):981-7;PMID:26771706

177. Nguyen DP, Xiong P, Pan S, Liu H, Guo M, Navarro, V, Kim S, **Bander NH**. Induction of prostate-specific membrane antigen (PSMA) expression and internalization of anti-PSMA monoclonal antibodies in human endothelial cells, *Molecular Cancer Research*, 2016 July pii: molcanres.0193.2016. [Epub ahead of print] PMID: 27458033.

178. McNeel DG; **Bander NH**; Beer TM; Drake CG; Fong L; Harrelson S; Kantoff PW; Madan RA; Oh WK; Peace, DJ; Petrylak DP; Porterfield H; Sartor O; Shore ND; Slovin SF; Stein MN; Vieweg J; Gulley J. The Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Prostate Carcinoma. *J for ImmunoTherapy of Cancer*, *under review*.

179. Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR, **Bander NH**, Larson SM, Zanzonico PB, Osborne JR. Targeting of radiolabeled **J591** antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. *EJNMMI Res*. 2016 Dec;6(1):7. doi: 10.1186/s13550-016-0164-0. Epub 2016 Jan 22. PMID: 26801327

PATENTS ISSUED (partial list)

1. United States Patent 4,713,352 (Dec. 15, 1987)

Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma

Inventors: Bander, Neil H.; Whitmore, Willet F.; Old, Lloyd J.

Assignee: Sloan-Kettering Institute for Cancer Research.

2. United States Patent 4,935,344 (Jun. 19, 1990)

Method for characterizing types of renal carcinoma and prognosis

Inventors: Bander; Neil H.; Cordon-Cardo, Carlos; Finstad, Connie L.; Whitmore, Willet F.; Melamed, Myron R.; Oettgen, Herbert F., Old; Lloyd J.

Assignee: Sloan-Kettering Institute for Cancer Research.

3. United States Patent 5,145,773 (Sept. 8, 1992)

Method to detect sensitivity to alpha-interferon therapy

Inventors: Albino, Anthony P.; Nanus, David M.; Bander, Neil H.; Pfeffer Lawrence M..

Assignee: Sloan-Kettering Institute for Cancer Research .

4. Canadian Patent 2, 261,018 (July 17, 1997)

Treatment and Diagnosis of Cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

5. United States Patent 5,773,292 (June 30, 1998)

Antibodies, binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood

Inventors: Bander, Neil H.

Assignee: Cornell University.

6. United States Patent 6,087,098 (July 11, 2000)

Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma

Inventors: McKiernan, James M.; Sawczuk, Ihor S.; Buttyan, Ralph; Bander, Neil H..

Assignee: The Trustees of Columbia University in the City of New York; Cornell Research Foundation, Inc.

7. United States Patent 6,107,090 (August 22, 2000)

Treatment and diagnosis of prostate cancer with antibodies to extracellular PSMA domains

Inventor: Bander, Neil H.

Assignee: Cornell Research Foundation, Inc.

8. United States patent 6,136,311 (October 24, 2000)

Treatment and Diagnosis of Cancer.

Inventor: Bander, Neil H.

Assignee: Cornell Research Foundation, Inc.

9. Australia Patent 733544 (August 30, 2001)

Treatment and Diagnosis of Cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

10. United States patent 6,299,598 (October 9, 2001)

Postprostatectomy suprapubic drainage catheter

Inventor: Bander, Neil H.

Assignee: Cook Urological, Inc.

11. New Zealand Patent 333683 (January 1, 2002)

Treatment and Diagnosis of Cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

12. Hong Kong Patent HK1062915 (May 30, 2002)

Modified Antibodies to Prostate Specific Membrane Antigen (PSMA) and Uses Thereof

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

13. Australian Patent 2002318169 (May 30, 2002)

Modified Antibodies to Prostate-specific Membrane Antigen and Uses Thereof

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

14. United States patent 6,451,532 (September 17, 2002)

Enhanced reverse transcriptase polymerase chain assay to detect MN antigen in patients with renal cell carcinoma

Inventor: McKiernan, James M.; Sawczuk, Ihor S.; Buttyan, Ralph; Bander, Neil H.

The Trustees of Columbia University in the City of New York; Cornell Research Foundation, Inc.

15. European Patent Application 2277542 (May 30, 2002)

Modified Antibodies to Prostate-Specific Membrane Antigen and Uses Thereof

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

16. United States patent 6,649,163 (November 18, 2003)

Treatment and Diagnosis of Cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

17. United States patent 6,653,129 (November 25, 2003)

Methods for the Isolation of Prostatic Epithelial Cells from a Biological Fluid

Inventors: Bander, N.H., Glode, M.L. and Suh, C.I.

Assignee: University of Colorado

18. EurAsia and Eastern Europe patent 004634 (June 24, 2004)

Treatment and diagnosis of cancer

Inventor: Bander, N.H. (US)

Assignee: Cornell Research Foundation, Inc.

19. United States patent 6,767,711 (July 27, 2004)

Treatment and diagnosis of prostate cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

20. United States patent 6,770,450 (August 3, 2004)

Treatment and diagnosis of cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

21. China patent 1165764 (September 8, 2004)
Treatment and Diagnosis of Cancer
Inventor: Bander, N.H.
Assignee: Cornell Research Foundation, Inc.

22. China Patent ZL97197912X (September 8, 2004)
Treatment and Diagnosis of Prostate Cancer
Inventor: Bander, N.H.
Assignee: Cornell Research Foundation, Inc.

23. Israel patent 127979 (February 25, 2005)
Antibodies and Antigen Binding Portions Thereof That Bind Prostate Specific Membrane
Antigen (PSMA) And Uses Thereof For Diagnosing Cancer
Inventor: Bander, N.H.
Assignee: Cornell Research Foundation, Inc.

24. New Zealand Patent 524036 (July 17, 2005)
Treatment and Diagnosis of Cancer
Inventor: Bander, N.H.
Assignee: Cornell Research Foundation, Inc.

25. Hong Kong Patent HK1025631 (July 17, 2005)
Treatment and Diagnosis of Cancer
Inventor: Bander, N.H.
Assignee: Cornell Research Foundation, Inc.

26. United States Patent #7,045,605 (Mat 16, 2006)
Modified Antibodies to Prostate-Specific Membrane Antigen and Uses Thereof
Inventor: Bander, N.H. et al
Assignee: Cornell Research Foundation, Inc.

27. Mexican Patent 233285 (December 21, 2005)
Treatment and Diagnosis of Cancer
Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

28. European Patent 0956506 B1 (March 1, 2006)

Treatment and Diagnosis of Cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

29. Austria Patent E319089 (March 1, 2006)

Treatment and Diagnosis of Cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

30. United States Patent 7,112,412 (September 26, 2006)

Treatment and diagnosis of prostate cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc

31. United States Patent 7,163,680 (January 16, 2007)

Treatment and diagnosis of prostate cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc

32. United States Patent 7,192,586 (March 20, 2007)

Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc

33. Chinese Patent ZL200410054422.3 (October 24, 2007)

An antibody or antigen binding portion thereof that binds ...

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

34. Chinese Patent ZL200410054422.3 (October 24, 2007)

An antibody or antigen binding portion thereof that binds prostate specific membrane antigen

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

35. Mexican Patent PA/a/2003/01084 (May 9, 2008)

Modified Antibodies to Prostate Specific Membrane Antigen and Uses Thereof

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

36. United States Patent 7,514,078 B2 (April 7, 2009)

Methods of treating Prostate Cancer with Anti-Prostate Specific membrane Antigens Antibodies

Inventor: Bander, N.H. (USA), Carr, Francis J (GB), Hamilton Anita (GB)

Assignee: Cornell Research Foundation, Inc.

37. United States Patent 7,666,414 (February 23, 2010)

Modified Antibodies to Prostate-Specific membrane Antigen and Uses Thereof

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

38. United States Patent 7,666,425 (February 23, 2010)

Treatment and Diagnosis of Prostate Cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

39. European Patent 1599228 (April 28, 2010)

Modified Antibodies to Prostate-Specific Membrane Antigen and Uses Thereof

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

40. Japanese Patent 4503102 (April 30, 2010)

Treatment and Diagnosis of Cancer

Inventor: Bander N.H.

Assignee: Cornell Research Foundation, Inc

41. Japanese Patent 4619651(November 5, 2010)

Modified Antibodies to Prostate-Specific Membrane Antigen and Uses Thereof

Inventor: Bander, N.H. et al

Assignee: Cornell Research Foundation, Inc.

42. Israeli Patent 162230 (January 3, 2011)

Antibodies and Antigen Binding Portions Thereof That Bind Prostate Specific Membrane Antigen (PSMA)

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

43. Canadian Patent 2,447,695 (July 16, 2014)

Modified Antibodies to Prostate-Specific Membrane Antigen And Uses Thereof

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

44. Japanese Patent 5627191 (August 7, 2014)

Treatment and Diagnosis of Prostate Cancer with Antibodies to the Extracellular Domain of PSMA

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

45. US Patent 8,951,737 (February 10, 2015)

Treatment and Diagnosis of Cancer

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation, Inc.

46. Israel Patent No. 201274

Modified Antibodies to Prostate-Specific Membrane Antigen and Uses Thereof

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation

47. Japanese Patent No. 5906090

Methods and Kits for Diagnosis of Cancer and Prediction of Therapeutic Value

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation

48. Japanese Patent No. 5969446

Methods and Kits for Diagnosis of Cancer and Prediction of Therapeutic Value

Inventor: Bander, N.H.

Assignee: Cornell Research Foundation